antibody found in the blood. The research further showed that IgG and neutralising antibody levels in previously infected participants were significantly higher after one dose than those in fully vaccinated volunteers with no history of infection.
A second dose did not increase the production of neutralising antibodies in previously infected volunteers. The high antibody levels after a single dose in naive participants suggest a benefit of delaying second dose administration to increase the number of people vaccinated, researchers said.
The researchers noted that evidence from other vaccines offers support for the one-shot approach. The AstraZeneca vaccine, for example, shows 76% efficacy after a single dose, and the Moderna and Pfizer